galunisertib galunisertib galunisertib (ly2157299) is a small molecular experimental cancer drug previously in development by eli lilly. it is a tgf-b inhibitor. development of galunisertib by eli lilly was discontinued in january 2020. galunisertibclinical dataroutes ofadministrationpoidentifiers iupac name 4-(5,6-dihydro-2-(6-methyl-2-pyridinyl)-4h-pyrrolo(1,2-b)pyrazol-3-yl)-6-quinolinecarboxamide cas number700874-72-2pubchem cid10090485chemspider8266022unii3okh1w5lzekeggd10437chebichebi:137064comptox dashboard (epa)dtxsid00220362 chemical and physical dataformulac22h19n5omolar mass369.428 g·mol−13d model (jsmol)interactive image smiles n1=cc=c(c2=cc(=cc=c12)c(=o)n)c1=c2n(n=c1c1c=cc=c(n=1)c)ccc2 inchi inchi=1s/c22h19n5o/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12h,3,6,11h2,1h3,(h2,23,28)key:ivrxnbxkwijuqb-uhfffaoysa-n galunisertib was investigated in a phase ii trial for treatment of hepatocellular carcinoma. pre-clinically, combination of galunisertib with pd-l1 blockade resulted in improved tumor growth inhibition.